MA34959B1 - Agomelatine cristalline mixte (forme viii) ,son procede de preparation et utilisation et composistion pharmaceutique la contenant - Google Patents

Agomelatine cristalline mixte (forme viii) ,son procede de preparation et utilisation et composistion pharmaceutique la contenant

Info

Publication number
MA34959B1
MA34959B1 MA36226A MA36226A MA34959B1 MA 34959 B1 MA34959 B1 MA 34959B1 MA 36226 A MA36226 A MA 36226A MA 36226 A MA36226 A MA 36226A MA 34959 B1 MA34959 B1 MA 34959B1
Authority
MA
Morocco
Prior art keywords
same
pharmaceutical composition
form viii
composition containing
agomelatin
Prior art date
Application number
MA36226A
Other languages
English (en)
Inventor
Yu Huang
Qing Long
Xueyan Zhu
Hanbin Shan
Zhedong Yuan
Xiong Yu
Original Assignee
Shanghai Insitute Of Pharmaceutical Industry
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Insitute Of Pharmaceutical Industry, Servier Lab filed Critical Shanghai Insitute Of Pharmaceutical Industry
Publication of MA34959B1 publication Critical patent/MA34959B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

CETTE INVENTION CONCERNE UNE AGOMÉLATINE CRISTALLINE MIXTE (FORME VIII), SON PROCÉDÉ DE PRÉPARATION ET UTILISATION ET UNE COMPOSITION PHARMACEUTIQUE LA CONTENANT, LEDIT CRISTAL MIXTE CONTENANT PRINCIPALEMENT UNE FORME CRISTALLINE VI D'AGOMÉLATINE. LE CRISTAL MIXTE EST STABLE ET A UNE BONNE REPRODUCTIBILITÉ ; ET IL S'AVÈRE, À L'ISSUE D'UN TEST DE STABILITÉ, SUPÉRIEUR À UNE FORME CRISTALLINE VI EN TERMES DE STABILITÉ. PAR CONSÉQUENT, LA FORME VIII SELON L'INVENTION PRÉSENTE UN AVANTAGE EN TERMES DE PRÉPARATION.
MA36226A 2011-03-23 2012-03-22 Agomelatine cristalline mixte (forme viii) ,son procede de preparation et utilisation et composistion pharmaceutique la contenant MA34959B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011100706340A CN102690209A (zh) 2011-03-23 2011-03-23 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
PCT/CN2012/072818 WO2012126386A1 (fr) 2011-03-23 2012-03-22 Agomélatine cristalline mixte (forme viii), son procédé de préparation et utilisation et composition pharmaceutique la contenant

Publications (1)

Publication Number Publication Date
MA34959B1 true MA34959B1 (fr) 2014-03-01

Family

ID=46855965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36226A MA34959B1 (fr) 2011-03-23 2012-03-22 Agomelatine cristalline mixte (forme viii) ,son procede de preparation et utilisation et composistion pharmaceutique la contenant

Country Status (30)

Country Link
US (1) US20140088197A1 (fr)
EP (1) EP2690088B1 (fr)
JP (1) JP6203171B2 (fr)
KR (1) KR20130136546A (fr)
CN (2) CN102690209A (fr)
AR (1) AR085915A1 (fr)
AU (1) AU2012231548B2 (fr)
BR (1) BR112013024022A2 (fr)
CA (1) CA2829690C (fr)
CY (1) CY1118751T1 (fr)
DK (1) DK2690088T3 (fr)
EA (1) EA023278B1 (fr)
ES (1) ES2626030T3 (fr)
GE (1) GEP201606567B (fr)
HK (1) HK1193086A1 (fr)
HR (1) HRP20170575T1 (fr)
HU (1) HUE034329T2 (fr)
LT (1) LT2690088T (fr)
MA (1) MA34959B1 (fr)
MD (1) MD4484C1 (fr)
ME (1) ME02731B (fr)
MX (1) MX355551B (fr)
MY (1) MY166444A (fr)
PL (1) PL2690088T3 (fr)
PT (1) PT2690088T (fr)
RS (1) RS55918B1 (fr)
SG (1) SG193305A1 (fr)
SI (1) SI2690088T1 (fr)
WO (1) WO2012126386A1 (fr)
ZA (1) ZA201306761B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
EP3027588B1 (fr) * 2013-07-29 2020-04-01 Les Laboratoires Servier Complexes d'agomélatine et d'acides sulfoniques, procédé de leur préparation et compositions pharmaceutiques qui les contiennent
CN104529804A (zh) * 2014-12-11 2015-04-22 连云港金康医药科技有限公司 阿戈美拉汀的新晶型
PL3075724T3 (pl) 2015-03-31 2023-12-27 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Stała postać agomelatyny
EP3466923A1 (fr) * 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Procédés de préparation d'agomélatine dans une forme cristalline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7498466B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (fr) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 Procédé pour la préparation d'agomélatine, cristaux d'agomélatine et leur procédé de préparation
CN101723844A (zh) * 2009-11-21 2010-06-09 浙江华海药业股份有限公司 一种阿戈美拉汀晶形b、它的制备方法和包含它的药物组合物
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
EP2319827A1 (fr) * 2009-11-09 2011-05-11 Ratiopharm GmbH Procédé pour la production d'une forme I polymorphe d'agomélatine
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101792400B (zh) * 2010-03-16 2013-01-30 华东师范大学 一种阿戈美拉汀的合成方法
CL2011001405A1 (es) * 2010-06-10 2012-03-30 Gador S A Conicet Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
WO2012046253A2 (fr) * 2010-10-08 2012-04-12 Msn Laboratories Limited Procédé de préparation de n-[2- (7-méthoxy-l-naphthyl) éthyl] acétamide et ses nouvelles formes cristallines
CN102452952A (zh) * 2010-11-03 2012-05-16 天津药物研究院 一种高纯度的i型阿戈美拉汀晶体制备方法

Also Published As

Publication number Publication date
MD4484B1 (ro) 2017-05-31
LT2690088T (lt) 2017-04-10
US20140088197A1 (en) 2014-03-27
EA023278B1 (ru) 2016-05-31
KR20130136546A (ko) 2013-12-12
MY166444A (en) 2018-06-27
GEP201606567B (en) 2016-11-10
CA2829690C (fr) 2016-08-09
AU2012231548B2 (en) 2015-11-19
PL2690088T3 (pl) 2017-09-29
ME02731B (fr) 2017-10-20
CA2829690A1 (fr) 2012-09-27
ZA201306761B (en) 2014-05-25
HRP20170575T1 (hr) 2017-06-30
BR112013024022A2 (pt) 2016-12-06
WO2012126386A1 (fr) 2012-09-27
EP2690088B1 (fr) 2017-02-22
EA201301065A1 (ru) 2014-02-28
JP6203171B2 (ja) 2017-09-27
CN103476743A (zh) 2013-12-25
PT2690088T (pt) 2017-03-20
SG193305A1 (en) 2013-10-30
EP2690088A4 (fr) 2014-09-17
RS55918B1 (sr) 2017-09-29
EP2690088A1 (fr) 2014-01-29
SI2690088T1 (sl) 2017-06-30
MD20130074A2 (en) 2014-03-31
MX2013010634A (es) 2013-10-07
CN103476743B (zh) 2015-02-25
MD4484C1 (ro) 2017-12-31
AR085915A1 (es) 2013-11-06
MX355551B (es) 2018-04-23
HK1193086A1 (en) 2014-09-12
DK2690088T3 (en) 2017-06-06
ES2626030T3 (es) 2017-07-21
CY1118751T1 (el) 2017-07-12
NZ615714A (en) 2016-03-31
CN102690209A (zh) 2012-09-26
HUE034329T2 (en) 2018-02-28
AU2012231548A1 (en) 2013-10-03
JP2014516921A (ja) 2014-07-17

Similar Documents

Publication Publication Date Title
MA34959B1 (fr) Agomelatine cristalline mixte (forme viii) ,son procede de preparation et utilisation et composistion pharmaceutique la contenant
Ruguo et al. Thermal analysis of four insect waxes based on differential scanning calorimetry (DSC)
Jarvius et al. Piperlongumine induces inhibition of the ubiquitin–proteasome system in cancer cells
RU2008126743A (ru) Способ получения фармацевтической композиции
HRP20050735B1 (hr) Dihidropteridinoni, metoda za njihovu proizvodnju i upotrebu u obliku lijekova
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
MA34958B1 (fr) Nouvelle forme cristalline vii d'agomelatine ,son procedes de preparation et utilisation et composition pharmaceutique la contenant
EA200700173A1 (ru) Пористые таблетки в качестве носителей для жидких композиций
JP2013534536A5 (fr)
MX2015011627A (es) Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos.
MX2013011627A (es) Analogos de acido epoxieicosatrienoico y metodos para fabricar y usar los mismos.
MY166378A (en) Zeoltic materials and methods for their preparation using alkenyltrialkylammonium compounds
JP2010510965A5 (fr)
EA200601373A1 (ru) Нитрат бутоконазола высокой степени чистоты с частицами заданного размера и способ его получения
Burstein et al. N-Amino acid linoleoyl conjugates: anti-inflammatory activities
MX2009008068A (es) Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene.
TR200504091T2 (tr) (7alfa,17alfa)-17-hidroksi-7-metil-19-nor-17-pregn-5(10)-en 20-in-3-on içeren yüksek saflıkta bileşim.
HUP0302905A2 (hu) Triazolo-epotilon-analógok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HK1060873A1 (en) Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor
ATE470669T1 (de) D-(17alpha)-13-ethyl-17hydroxy-18,19-dinorpregn 4-ene-20-yne-3-one in form des reinen 3e- und 3z- oximes sowie das verfahren zur herstellung der mischung der isomere wie auch der reinen isomere
KR20220082873A (ko) 항암제로서 엔-아실화된 히스티딘 디펩티드
CN107014921B (zh) 苏拉明钠的高效液相检测方法
CN103705933A (zh) 奥卡西平药物组合物及制备方法
RU2009146759A (ru) Способ электроэрозионного легирования
MY190816A (en) A process for purifying methyl ester sulphonate